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ABSTRACT 
Chronic activation of the renin angiotensin system promotes hypertension, renal 
microvascular dysfunction, tissue hypoxia and inflammation. We found previously 
that the injurious response to excess angiotensin II (ANGII) is greater in F344 rats, 
whereas Lewis rats are renoprotected, despite similar hypertension. We further 
identified p2rx7, encoding the P2X7 receptor (P2X7R), as a candidate gene for 
differential susceptibility and here we have tested the hypothesis that activation of 
P2X7R promotes vascular dysfunction under high ANGII tone.  
14-day infusion of ANGII at 30ng/min into F344 rats increased blood pressure by 
~15mmHg without inducing fibrosis or albuminuria. In vivo pressure natriuresis was 
suppressed, medullary perfusion reduced by ~50% and the cortico-medullary 
oxygenation gradient disrupted. Selective P2X7R antagonism restored pressure 
natriuresis, promoting a significant leftward shift in the intercept and increasing the 
slope. Sodium excretion was increased 6 fold and blood pressure normalized. The 
specific P2X7R antagonist AZ11657312 increased renal medullary perfusion, but 
only in ANGII-treated rats. Tissue oxygenation was improved by P2X7R blockade, 
particularly in poorly oxygenated regions of the kidney. Activation of P2X7R induces 
microvascular dysfunction and regional hypoxia when ANGII is elevated. These pro-
inflammatory effects may contribute to progression of renal injury induced by chronic 
ANGII. 
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INTRODUCTION 
Chronic kidney disease (CKD) affects ~10% of the world’s population1 and increases 
the risk of serious cardiovascular events2. The etiology of CKD is varied and its 
pathophysiology complex. Renal hypoxia due to reduced perfusion of the medulla3, 4 
may be a common underlying early event, triggered or exacerbated by inflammation5, 
6. 
CKD is heritable but identifying candidate genes for complex diseases in a 
heterogeneous human population is challenging7. Rodent models replicating key 
aspects of CKD provide a powerful tool to help identify genetic contributions to 
injury.8 In that context the Ren2 transgenic rat9 has provided a platform for examining 
the pathways associated with malignant hypertensive end-organ injury, which has 
been documented in an extensive literature.10 Refining the approach by placing Ren2 
cDNA expression under the control of an inducible cytochrome P450 promoter, 
allowed dose-dependent activation of the renin-angiotensin system by dietary 
administration of a non-toxic xenobiotic.11 This improved experimental control permits 
the sequence of events leading to renal injury to be defined more precisely: in the 
early phase, renal hemodynamics are stable, tubular sodium transport is increased 
and injury is localized predominantly to the pre-glomerular arteries and renal 
microvasculature12. 
In both the constitutive and inducible forms of this model the extent of injury is 
strongly influenced by genetic background: F344 rats are prone to injury; the Lewis 
strain background confers renoprotection.13, 14 We exploited the differential 
susceptibility of these inbred strains to map Quantitative Trait Loci (QTL) for 
malignant hypertension and its sequela13, 15. One QTL was then captured in 
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reciprocal congenic lines to identify Ace (encoding angiotensin converting enzyme) 
as a major modifier gene for renal injury14. The circulating and local concentration of 
angiotensin II (ANGII) is increasingly recognized as an important factor in CKD15.   
In the cyp1a1-Ren2 rat, blockade of AT1 receptors prevents hypertension, but is only 
partially protective against renal vascular injury12 and it is likely that multiple 
pathways contribute to injury. Therefore we re-mined an exon microarray14 to 
compare renal gene expression in non-hypertensive, non-injured F344 and Lewis 
rats. A bioinformatics enrichment approach confirmed Ace as the top ranked 
candidate gene, but also identified P2rx7, which encodes the purinergic P2X7 
receptor (P2X7R), as the next leading candidate gene for susceptibility to 
hypertensive renal injury.16 
Purinergic signaling exerts powerful physiological effects on renal function17 and the 
hypothesis that sustained activation of P2X7R contributes to hypertensive renal 
vascular injury and dysfunction is attractive. Several studies indicate that P2X7R 
activation contributes to chronic inflammatory disorders: activation of P2X7R 
promotes the formation of the NLRP3 inflammasone18 and stimulates release of 
inflammatory cytokines19. Moreover, P2X7R expression is increased in human and 
experimental kidney disease20. Pharmacological blockade or genetic deletion of this 
receptor protects against antibody-mediated glomerular inflammation21 and 
hypertensive renal injury22 in rodents. Renoprotection is associated with reduced 
numbers of renal macrophages and has been attributed to a direct anti-inflammatory 
effect of P2XR7 antagonism.  
However, P2rx7 mRNA is abundantly expressed under normal, non-inflammatory, 
conditions on endothelial cells,23, 24 and the receptor is immunolocalized to the 
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endothelium of the pre-glomerular vasculature.16 P2X7R is also expressed in the 
vasa recta25 and functional data indicate that receptor activation causes contraction 
of renal medullary pericytes.26 Importantly, the interstitial concentration of 
extracellular ATP, the endogenous ligand for P2X7R, is markedly increased by 
elevated renal perfusion pressure27 and by chronic infusion of ANGII.28 This lead us 
to propose a novel and alternative hypothesis in which the early injurious event of 
sustained P2X7R activation is vascular in origin: reduced perfusion of the renal 
medulla would promote hypoxia29 and impair blood pressure control through a 
suppressed pressure-natriuresis response.30  
Therefore, we determined the effect of P2X7R antagonism on the pressure-
natriuresis and renal hemodynamic responses in F344 rats chronically infused with 
ANGII. Blood Oxygenation Level-Dependent magnetic resonance imaging (BOLD 
MRI) was used to assess oxygenation in the renal cortex and medulla. Our results 
suggest that tonic P2X7R activation contributes to renal vasoconstriction in rats with 
high ANGII tone. Blockade of the receptor increases renal oxygenation and P2XR7 
inhibitors may have a therapeutic benefit in addition to their known anti-inflammatory 
actions. 
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RESULTS 
P2X7R antagonism improves the pressure-natriuresis response in ANGII-
treated rats 
After 14 days of ANGII infusion, mean blood pressure (MBP) was increased by 
~15mmHg compared with vehicle infused rats (Figure 1A). Sodium excretion 
measured under anesthesia was not different from control rats (Figure 1B) but 
chronic ANGII significantly (P<0.01) suppressed the elevation (y-intercept) of the 
pressure-natriuresis (Figure 1C) and pressure-diuresis (Figure 1D) relationships, as 
shown previously.31 
Acute infusion of the selective P2X7R antagonist Brilliant Blue G (BBG)32 reduced 
blood pressure in ANGII treated rats to a level similar to control animals (Figure 1A); 
sodium excretion was increased ~6-fold by BBG (Figure 1B). BBG also caused a 
significant (P<0.05) leftward shift in both pressure-natriuresis and pressure-diuresis 
curves and the gradient of response was significantly improved (P<0.01) compared 
with ANGII-treated rats receiving vehicle (Figure 1C/D). Renal blood flow, measured 
by a Doppler flow probe around the left renal artery was not affected by increased 
blood pressure in any of the experimental groups; glomerular filtration rate was also 
unchanged during pressure-natriuresis (Supplemental Figure 1).  
Chronic ANGII treatment and P2X7R expression 
In control rats P2X7R expression was localized to the vascular endothelium of the 
preglomerular arteries, such as the segmental (Figure 2 A/B) and interlobar arteries 
(Figure 2C/D). P2X7R staining was also noted in the smooth muscle of the afferent 
arteriole (Figure 2E/F). In control rats there were low levels of glomerular and tubular 
expression of P2X7R (Figure 2E), which became more evident after chronic ANGII 
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treatment (Figure 2F). ANGII also induced focal expression in the vascular smooth 
muscle of the pre-glomerular arteries (Figure 2Bi). However, at the whole kidney 
level, mRNA and protein expression of P2X7R was unaffected by ANGII infusion 
(Supplemental Figure 2). As anticipated, 14 days of ANGII infusion did not induce 
gross renal injury, there was no evidence of fibrosis, quantified by Sirius red staining, 
and there was no albuminuria (data not shown). ANGII infusion can promote vascular 
hypertrophy, but here the cross sectional vessel wall area was not different between 
groups. ANGII did, however, induce vacuolization of pre-glomerular arteries (Figure 3 
A/B). This smooth muscle injury was significantly more extensive in ANG II treated 
rats than controls (Figure 3C/D) and is suggestive of vasospasm. ANGII infusion also 
caused glomerular accumulation of ED-1 positive macrophages (Figure 3E), 
suggesting some inflammatory cell infiltrate after 2 weeks of treatment.   
P2X7R antagonism increases renal medullary perfusion in ANGII-treated rats 
The effect of P2X7R antagonism on renal and intrarenal blood flow was measured in 
a separate group of rats infused with ANGII or vehicle for 14 days. ANGII again 
caused a modest increase in MBP (ANGII= 133±2; Vehicle= 118±2 mmHg; P<0.01) 
and a reduction in heart rate (ANGII 380±4; Vehicle 406±13 bpm; P<0.05) but left 
renal artery blood flow (ANGII= 6.64±0.5; Vehicle= 6.24±0.44 ml/min) and renal 
vascular resistance (ANGII= 21.0±1.9; Vehicle= 19.2±1.1 mmHg/ml.min-1) were not 
affected. Medullary microvascular perfusion was reduced by ~50% in ANGII-treated 
rats (ANGII= 6.5±2.7; Vehicle= 12.02±3.5 TPU; P<0.05). After these baseline 
recordings, the effect of a specific and potent P2X7R antagonist AZ11657312, 33 was 
assessed. Exemplar recordings of AZ11657312 on renal hemodynamics in an ANGII-
treated rat are shown in Supplemental Figure 3; group mean data were obtained by 
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normalizing the area under the response curve in each rat to changes induced by 
equivalent volume injections of the vehicle (1% DMSO in saline). Two-way ANOVA 
indicated a significant overall effect of AZ11657312 (P<0.001) on MBP, renal artery 
blood flow and medullary perfusion. In control rats, IV injection of AZ11657312 
caused a reduction in MABP (Figure 4A) and an increase in renal blood flow 
compared with vehicle, but only at the highest dose (Figure 4B). The effect of 
AZ11657312 was not significantly greater from that of vehicle at any dose used 
(Figure 4C). In ANGII-infused rats AZ11657312 induced a dose-dependent reduction 
of MABP (Figure 4A), accompanied by a dose-dependent increase in both renal 
blood flow and medullary perfusion (Figure 4B & C).  
The renal hemodynamic effect of P2X7R antagonism is nitric oxide-dependent 
To test whether the vasoactive effects of P2X7R blockade were dependent on nitric 
oxide (NO) production, we injected the nitric oxide synthase (NOS) inhibitor, Nω-
Nitro-L-arginine methyl ester hydrochloride (L-NAME) into ANGII-treated rats prior to 
administration AZ11657312. In control rats, the modest hemodynamic effects of 
AZ11657312 were not significantly affected by NOS inhibition (Supplemental Figure 
4).  
In the ANGII-treated rats, L-NAME did not change the hypotensive effect of 
AZ11657312 (Figure 5A) and therefore the blood pressure response to systemic 
P2X7R antagonism is independent of NO production.  L-NAME reduced, but did not 
abolish, the effect of AZ11657312 on renal artery blood flow (Figure 5B) and 
medullary perfusion (Figure 5C). This indicates that the vasodilation of the renal 
vasculature induced by P2X7R antagonism is only partially dependent on NO 
production.  
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P2X7R antagonism increases renal oxygenation in ANGII-treated rats 
We used BOLD MRI to assess the effect of P2X7R antagonism on the renal map of 
R2*, which is inversely related to tissue pO2. An anatomically unbiased k-means 
clustering approach was used for post-acquisition analysis, because this approach 
identifies regions sharing quantitative “nearness” or “similarity” regardless of their 
underlying spatial location, and is not subject to bias that can be associated with 
user-led analysis.34 Moreover, this approach includes all of the data within the image 
to provide a global map of oxygenation homogeneity within the kidney of each rat. 34 
In control rats, the renal R2* map segregated	  two clusters of homogeneity that largely 
corresponded to discrete anatomical regions of the kidney. The low R2* cluster (high 
oxygenation) was mainly situated in the cortex; the high R2* cluster (low 
oxygenation) localized primarily to the medulla. Injection of the P2X7R antagonist 
BBG did not affect the R2* signal within either of these clusters (Figure 6A and B). 
Chronic ANGII infusion markedly altered the R2* map within the kidney, as we have 
reported before34. Two clusters were segregated since divergence is assured using 
this algorithm. However, these clusters of high and low R2* did not overlay onto 
discrete anatomical regions of the kidney, indicating dissipation of the cortico-
medullary oxygenation gradient. In this setting, acute P2X7R antagonism produced a 
significant fall in R2* in both clusters (ANOVA P<0.01), reflecting increased 
oxygenation. This effect was particularly evident in the cluster with low baseline pO2 
levels, in which post-hoc comparisons also reached statistical significance  (Figure 
6B). 
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DISCUSSION 
Increased P2X7R expression is associated with renal injury in humans20 and 
experimental models of type I diabetes, hypertension,22, 35, 36 and glomerular 
disease21. This receptor is highly expressed in immune cells, playing a key role in the 
activation of macrophages, T- and B- lymphocytes.37 Injured cells also express the 
receptor, which in this setting is usually pro-apoptotic or cytotoxic.21, 38 Not 
surprisingly, P2X7R is an attractive therapeutic target to reduce inflammation in 
CKD.39 Our data suggest that additional benefit may accrue from blockade of renal 
P2X7R distinct from a direct anti-inflammatory effect: antagonism of the receptor in 
hypertensive rats reduced renal vascular resistance, consistent with expression in 
pre-glomerular arteries and arterioles.  P2X7R antagonism also increased both 
perfusion and oxygenation of the medulla, which are beneficial outcomes in CKD.29 
P2X7R blockade additionally improved the pressure-natriuresis response in 
hypertensive rats, which is an important blood pressure regulating mechanism.40 The 
interpretation of these data rests on the selectivity of the P2X7R antagonists, BBG 
and AZ11657312. BBG is a potent inhibitor of rat P2X7R (IC50 = 10 nM) but can also 
block the closely related P2X4R, albeit with 1000-fold lower selectivity. Non-
purinergic off-target effects have also been reported41 and we cannot exclude the 
possibility that P2X7R-independent effects contribute to the hemodynamic actions of 
BBG observed here. Nevertheless, the specific P2X7R inhibitor AZ1165731233, 
which does not inhibit P2X4R,  evoked vasoactive effects qualitatively similar to those 
induced by BBG and together our findings strongly suggest that P2X7R activation 
can influence renal hemodynamic function.  
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P2X7R is expressed in vascular endothelial cells23, 24 and in the normal rat kidney it 
has been immunolocalized to the endothelium of the pre-glomerular arteries and the 
afferent arteriole.16 Functional studies are limited, but P2X7R may form cation 
channels in the endothelium42 and on activation induce NO production.43 P2X4R 
activation may also contribute to increase NO formation.44 P2X7R can also influence 
vascular reactivity indirectly by promoting the release of cytokines, particularly IL-1β, 
from endothelial cells, dependent on inducible NO synthase (iNOS) activation.45  
The current study in rats with high ANGII tone suggests that P2X7R activation exerts 
a tonic vasoconstriction of the renal artery and medullary microcirculation. This may 
contribute to the renal vasodilation induced by PPADS in ANGII rats.46. PPADS is a 
broad-spectrum P2 receptor antagonist but has high affinity at the rat P2X7R. The 
vasodilatation following P2X7R antagonism was partially dependent on NO formation 
by NOS. It is also possible that this vasodilatation reflects inhibition of the receptor in 
the smooth muscle, rather than the endothelium. Smooth muscle expression is 
normally low47, but some focal P2X7R immunoreactivity was observed in the present 
study after chronic ANGII infusion, in keeping with previous data from the 
hypertensive Ren2 transgenic rat.36  
The pressure-natriuresis response describes the mechanism by which increased 
renal perfusion pressure induces an increase in sodium excretion. In the current 
study, increased sodium excretion largely reflects inhibition of tubular sodium 
reabsorption, since renal blood flow and GFR were effectively auto-regulated during 
the applied increases in blood pressure.  Inhibition of tubular reabsorption is well 
documented but the underlying mechanisms are incompletely defined.40 Intrarenal 
paracrine signaling by ATP may mediate some aspects of the pressure-natriuresis 
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response25, but the current study suggests that tonic P2X7R activation suppresses 
this relationship and is detrimental to blood pressure control in ANGII-treated rats. 
P2X7R antagonism caused a marked improvement in the pressure-natriuresis. The 
leftward shift in the relationship can be attributed to vasodilation; several 
mechanisms could account for the improved gradient of the response. First, 
interstitial inflammation suppresses pressure natriuresis48 and the beneficial effect of 
BBG could reflect acute anti-inflammatory actions of P2X7R inhibition. This seems 
unlikely to be the major effect here because the response was too rapid and 
inflammation in our model is mild. Second, P2X7R activation increases the 
generation of reactive oxygen species49, which reduce blood flow in the medullary 
vasa recta and impair the pressure-natriuresis response.50 Third, P2X7R blockade 
increases blood flow directly by alleviating constriction of the vasa recta26 This is an 
attractive hypothesis, because extracellular ATP is an established regulator of 
microvascular function.51 P2X7R is expressed in the vasa recta25 and causes 
constriction of the abluminal pericytes that control blood flow through the capillary 
network.26 Our data offer some support for this hypothesis because systemic 
intravenous injection of AZ11657312 increased medullary microvascular perfusion. 
Nevertheless, this effect was only observed under high ANGII tone, a condition that 
increases interstitial ATP concentrations,28 and it may be that the influence of P2X7R 
on microvasculature function is normally small. P2X7R antagonism also improved 
renal oxygenation in ANGII-treated rats and this beneficial effect was particularly 
evident in high R2* cluster, i.e. in areas of the kidney that are relatively poorly 
oxygenated. It is not, however, possible, to attribute this improved oxygenation solely 
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to increased tissue perfusion as a reduction in active tubular transport may also be a 
contributory factor.  
Recent studies have reported a beneficial effect of P2X7R antagonism in the Dahl 
salt-sensitive rat model of hypertension35 and of P2X7R ablation in the DOCA model 
in mice.22 BBG almost abolished interstitial fibrosis and albuminuria in these settings 
and this cannot be entirely attributed to a reduction in barotrauma, because the 
reduction in blood pressure was modest.  Interestingly, there was also a reduction in 
the number of infiltrating immune cells (mainly macrophages) in the rats treated with 
BBG, and the authors postulated that this was the mechanism of renoprotection. The 
generation of a hypoxic microenvironment in the renal medulla is pro-inflammatory 
and may be an early pathway to kidney injury.52  
Taken together, these studies suggest that P2X7R antagonism may affect both 
inflammation and vasoconstriction. First, a reduction in blood pressure ameliorates 
barotrauma of the glomerulus and renal microvasculature; second, increased 
perfusion of the renal medulla restores blood pressure control and minimizes 
hypoxia; third, P2X7R antagonism may also reduce the immune cell response and 
local inflammation. Thus, P2X7R antagonism may have broad therapeutic value in 
renal disease.  
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METHODS 
Procedures were performed under the 1986 UK Home Office Animals (Scientific 
Procedures) Act, following local ethical review. Experiments were performed on male 
F344/NCrl rats (Charles River, UK) with free access to standard chow (0.25% 
sodium) and water. Osmotic minipumps (model 2002; Alzet, UK) were implanted 
subcutaneously under isofluorane anesthetic with vetergesic analgesic. Minipumps 
delivered ANGII (30ng/min) or saline vehicle and experiments were performed 11-14 
days after implant. 
Acute pressure-natriuresis was measured under terminal thiobutabarbital 
anesthesia  (Inactin; 120mg/kg IP). The right jugular vein was canulated for infusion 
of 0.9% NaCl (50μl/min/100g during surgery; 33μl/min/100g after surgery) or saline 
containing Brilliant Blue G (50μg/min/100g). The left femoral artery was cannulated to 
record blood pressure (MLT844; Capto, Norway) at 1 kHz (Powerlab; AD 
Instruments, UK). A midline laparotomy was performed and a Doppler transit time 
probe (MA1PRB; Transonic, USA) was placed around the around the left renal artery 
and covered in acoustic gel to optimize coupling. Core body temperature was 
maintained at 37°C using a servo-controlled heating blanket. Surgical preparation 
took ~1.5 hours and was followed by a 60-minute equilibration period. Urine 
collections were then made over 3 sequential periods, each of 30 minutes. After the 
first (baseline) collection, blood pressure was acutely increased by ligation of the 
superior mesenteric artery and urine collected. The coeliac artery was then ligated, 
after which the final urine collection was made. For each period urine was collected 
under mineral oil via a bladder catheter to determine flow rate. Urinary sodium 
concentration was measured by ion-sensitive electrode (InSight; QBC Europe). In a 
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subset of rats (n=4 per group), creatinine concentration was measured in each urine 
sample and in a plasma sample drawn at the end of the experiment. Creatinine was 
determined using the creatininase/creatinase specific enzymatic method using a 
commercial kit (Alpha Laboratories Ltd, UK) adapted for use on a Cobas Fara 
centrifugal analyser (Roche Diagnostics Ltd, UK). Creatinine clearance was 
calculated to provide an estimate of glomerular filtration rate.  
AZ11657312 cumulative dose-response studies were performed in anaesthetized 
rats as above. The renal jugular vein was cannulated (PE50 tubing) for infusion of 
0.9% NaCl and a second cannula (PE10) inserted for drug injection. Blood pressure 
was measured at the left femoral artery, renal blood flow at the left renal artery, as 
before. Additionally, an optical Doppler flux probe (Type M monfibre probe, 
Transonic, USA) was advanced into the renal medulla to measure microvascular 
perfusion. Probe position was confirmed post-mortem. Surgical preparation took ~1.5 
hours and was followed by a 60-minute equilibration period. AZ11657312 was 
injected intravenously in a 0.1ml of vehicle (1% DMSO in saline) and doses were 
administered in ascending order, preceded and followed by injection of the vehicle 
alone. Measurements were made over a period of 30-60 minutes.  
BOLD MRI was performed as previously described.34 Three sequential baseline 
scans were performed, after which BBG (40mg/kg) was administered by tail vein 
injection. Ten further scans were obtained. Total scan time was ~40mins. T2* maps 
were constructed followed by three-step image registration (global & intensity based) 
and motion artifact (Hampel identifier) quality control.  
k-means clustering analysis. Automated image segmentation was performed using 
a k-means clustering algorithm as previously described.34 This identifies k-clusters 
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within a multi-dimensional space using Euclidean distance. Given a set of points, the 
target of the algorithm is to find k cluster-centers such that the sum of square 
distances of each point to its closest cluster centre is a minimum. The (local) 
minimum is searched for in an iterative manner, the two steps of which are 1) the 
association of the points with their closest cluster centers, and 2) the updating of the 
cluster centers such that the sum of square distances to the associated points is 
minimized. Since the final cluster configuration can be dependent on that of the initial 
cluster configuration, we previously established the lowest number insensitive to the 
starting conditions. The present dataset found 10 random initial conditions to fit this 
condition, thus for each scan set we ran the algorithm and saved the final 
configuration as that with the lowest sum of intracluster distances.  
Our previous analysis was performed using k=1, 2, 3 up to 13 in order to identify the 
value of k such that the increase in explained variance of k+1 clusters was <50% of 
the additional variance explained by the kth cluster. k =2 was chosen, as the addition 
of a third cluster did not contribute sufficiently to an increase in explained variance. 
Each time series required ~50ms to converge when run in MATLAB on a standard 
desktop computer.  
Renal injury scoring was performed on hematoxylin & eosin stained sections: all 
embedded tissues were sectioned and stained in the same run. Vacuoles were close 
to circular edges and displaced nuclei. Total number of vacuoles counted per vessel 
was normalised to vessel thickness: this scoring was performed under single-blind 
conditions. 
Macrophage staining was performed using CD68 antibody (Serotec, UK; 1:500) 
and quantified using the automated detection tool ImmunoRatio normalised to 
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haematoxylin positive staining within individual glomeruli. At least 30 glomeruli were 
analysed per experimental group. Immunolocalisation of P2X7R used a rabbit anti-rat 
polyclonal antibody (APR-004, Alomone Laboratory, Israel) at 1:2000. This antibody 
is raised against an epitope on the intracellular c-terminal of the receptor, a region 
unique among P2X receptors and has been validated in both heterologous 
expression systems in in P2X7R null mice (see53 for review).  
Statistics: Data are presented as mean ± SEM or median and inter-quartile range, 
as stated. Statistical analysis was by repeated measures ANOVA, t-test or Mann 
Whitney U test, as stated. For ANOVA, post hoc comparisons were made using 
Sidak’s multiple comparison test. 
ACKNOWLEDGEMENTS 
We thank Dr Forbes Howie for creatinine measurements and AstraZeneca for 
providing AZ11657312. Part of this work was presented as an abstract at the 
Experimental Biology 2015 meeting in Boston, USA.   
DISCLOSURE 
RJU is currently on secondment as Chief Scientist to Cardiovascular and Metabolic 
Diseases (iMed CVMD) R&D, AstraZeneca, Mölndal, Sweden. FWKT has received 
research funding from AstraZeneca.  
	  	  
18	  
REFERENCES 
1. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global 
dimension and perspectives. Lancet 2013; 382: 260-272. 
2. Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney 
disease: from subspecialty to global health burden. Lancet 2013; 382: 158-169. 
3. Eckardt KU, Bernhardt WM, Weidemann A, et al. Role of hypoxia in the 
pathogenesis of renal disease. Kidney Int Suppl 2005: S46-51. 
4. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of 
chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008; 74: 
867-872. 
5. Cachofeiro V, Goicochea M, de Vinuesa SG, et al. Oxidative stress and 
inflammation, a link between chronic kidney disease and cardiovascular disease. 
Kidney Int Suppl 2008: S4-9. 
6. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant 
stress and inflammation in patients with moderate to severe chronic kidney disease. 
Kidney Int 2004; 65: 1009-1016. 
7. Drawz PE, Sedor JR. The genetics of common kidney disease: a pathway 
toward clinical relevance. Nat Rev Nephrol 2011; 7: 458-468. 
8. Schulz A, Kreutz R. Mapping genetic determinants of kidney damage in rat 
models. Hypertens Res 2012; 35: 675-694. 
9. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats 
harbouring the mouse Ren-2 gene. Nature 1990; 344: 541-544. 
10. Mullins LJ, Bailey MA, Mullins JJ. Hypertension, kidney, and transgenics: a 
fresh perspective. Physiol Rev 2006; 86: 709-746. 
	  	  
19	  
11. Kantachuvesiri S, Fleming S, Peters J, et al. Controlled hypertension, a 
transgenic toggle switch reveals differential mechanisms underlying vascular 
disease. J Biol Chem 2001; 276: 36727-36733. 
12. Ashek A, Menzies RI, Mullins LJ, et al. Activation of thiazide-sensitive co-
transport by angiotensin II in the cyp1a1-Ren2 hypertensive rat. PLoS One 2012; 7: 
e36311. 
13. Kantachuvesiri S, Haley CS, Fleming S, et al. Genetic mapping of modifier loci 
affecting malignant hypertension in TGRmRen2 rats. Kidney Int 1999; 56: 414-420. 
14. Liu X, Bellamy CO, Bailey MA, et al. Angiotensin-converting enzyme is a 
modifier of hypertensive end organ damage. J Biol Chem 2009; 284: 15564-15572. 
15. Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone 
system in chronic kidney disease. Am J Nephrol 2010; 31: 541-550. 
16. Menzies RI, Unwin RJ, Dash RK, et al. Effect of P2X4 and P2X7 receptor 
antagonism on the pressure diuresis relationship in rats. Front Physiol 2013; 4: 305. 
17. Burnstock G, Evans LC, Bailey MA. Purinergic signalling in the kidney in 
health and disease. Purinergic signalling 2014; 10: 71-101. 
18. Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the 
inflammasome in response to toxins and ATP. Nature 2006; 440: 228-232. 
19. Ferrari D, Pizzirani C, Adinolfi E, et al. The P2X7 receptor: a key player in IL-1 
processing and release. J Immunol 2006; 176: 3877-3883. 
20. Turner CM, Tam FW, Lai PC, et al. Increased expression of the pro-apoptotic 
ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol 
Dial Transplant 2007; 22: 386-395. 
21. Taylor SR, Turner CM, Elliott JI, et al. P2X7 deficiency attenuates renal injury 
in experimental glomerulonephritis. J Am Soc Nephrol 2009; 20: 1275-1281. 
	  	  
20	  
22. Ji X, Naito Y, Weng H, et al. P2X7 deficiency attenuates hypertension and 
renal injury in deoxycorticosterone acetate-salt hypertension. Am J Physiol Renal 
Physiol 2012; 303: F1207-1215. 
23. Ray FR, Huang W, Slater M, et al. Purinergic receptor distribution in 
endothelial cells in blood vessels: a basis for selection of coronary artery grafts. 
Atherosclerosis 2002; 162: 55-61. 
24. Yamamoto K, Korenaga R, Kamiya A, et al. P2X(4) receptors mediate ATP-
induced calcium influx in human vascular endothelial cells. Am J Physiol Heart Circ 
Physiol 2000; 279: H285-292. 
25. Menzies RI, Unwin RJ, Bailey MA. Renal P2 receptors and hypertension. Acta 
Physiol (Oxf) 2015; 213: 232-241. 
26. Crawford C, Kennedy-Lydon TM, Callaghan H, et al. Extracellular nucleotides 
affect pericyte-mediated regulation of rat in situ vasa recta diameter. Acta Physiol 
(Oxf) 2011; 202: 241-251. 
27. Nishiyama A, Majid DS, Taher KA, et al. Relation between renal interstitial 
ATP concentrations and autoregulation-mediated changes in renal vascular 
resistance. Circ Res 2000; 86: 656-662. 
28. Graciano ML, Nishiyama A, Jackson K, et al. Purinergic receptors contribute 
to early mesangial cell transformation and renal vessel hypertrophy during 
angiotensin II-induced hypertension. Am J Physiol Renal Physiol 2008; 294: F161-
169. 
29. Brezis M, Rosen S. Hypoxia of the renal medulla--its implications for disease. 
N Engl J Med 1995; 332: 647-655. 
 
	  	  
21	  
30. Mattson DL. Importance of the renal medullary circulation in the control of 
sodium excretion and blood pressure. Am J Physiol Regul Integr Comp Physiol 2003; 
284: R13-27. 
31. Wang CT, Chin SY, Navar LG. Impairment of pressure-natriuresis and renal 
autoregulation in ANG II-infused hypertensive rats. Am J Physiol Renal Physiol 2000; 
279: F319-325. 
32. Jiang LH, Mackenzie AB, North RA, et al. Brilliant blue G selectively blocks 
ATP-gated rat P2X(7) receptors. Mol Pharmacol 2000; 58: 82-88. 
33. Cruwys S, Midha A, Rendall E, et al. Antagonism of the P2X7 receptor 
attenuates joint destruction in a model of arthritis. Am Coll Rheumatol Abstr 2007: 
1772. 
34. Menzies RI, Zammit-Mangion A, Hollis LM, et al. An anatomically unbiased 
approach for analysis of renal BOLD magnetic resonance images. Am J Physiol 
Renal Physiol 2013; 305: F845-852. 
35. Ji X, Naito Y, Hirokawa G, et al. P2X(7) receptor antagonism attenuates the 
hypertension and renal injury in Dahl salt-sensitive rats. Hypertens Res 2012; 35: 
173-179. 
36. Vonend O, Turner CM, Chan CM, et al. Glomerular expression of the ATP-
sensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int 2004; 66: 
157-166. 
37. Lister MF, Sharkey J, Sawatzky DA, et al. The role of the purinergic P2X7 
receptor in inflammation. J Inflamm (Lond) 2007; 4: 5. 
38. Goncalves RG, Gabrich L, Rosario A, Jr., et al. The role of purinergic P2X7 
receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. 
Kidney Int 2006; 70: 1599-1606. 
	  	  
22	  
39. Arulkumaran N, Unwin RJ, Tam FW. A potential therapeutic role for P2X7 
receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin 
Investig Drugs 2011; 20: 897-915. 
40. Ivy JR, Bailey MA. Pressure natriuresis and the renal control of arterial blood 
pressure. J Physiol 2014; 592: 3955-3967. 
41. Katrahalli U, Kalanur SS, Seetharamappa J. Interaction of bioactive 
coomassie brilliant blue g with protein: insights from spectroscopic methods. Sci 
Pharm 2010; 78: 869-880. 
42. Ramirez AN, Kunze DL. P2X purinergic receptor channel expression and 
function in bovine aortic endothelium. Am J Physiol Heart Circ Physiol 2002; 282: 
H2106-2116. 
43. Oliveira SD, Coutinho-Silva R, Silva CL. Endothelial P2X7 receptors' 
expression is reduced by schistosomiasis. Purinergic signalling 2013; 9: 81-89. 
44. Yamamoto K, Korenaga R, Kamiya A, et al. Fluid shear stress activates 
Ca(2+) influx into human endothelial cells via P2X4 purinoceptors. Circ Res 2000; 
87: 385-391. 
45. Kanno K, Hirata Y, Imai T, et al. Regulation of inducible nitric oxide synthase 
gene by interleukin-1 beta in rat vascular endothelial cells. Am J Physiol 1994; 267: 
H2318-2324. 
46. Franco M, Bautista R, Tapia E, et al. Contribution of renal purinergic receptors 
to renal vasoconstriction in angiotensin II-induced hypertensive rats. Am J Physiol 
Renal Physiol 2011; 300: F1301-1309. 
47. Lewis CJ, Evans RJ. P2X receptor immunoreactivity in different arteries from 
the femoral, pulmonary, cerebral, coronary and renal circulations. J Vasc Res 2001; 
38: 332-340. 
	  	  
23	  
48. Franco M, Tapia E, Bautista R, et al. Impaired pressure natriuresis resulting in 
salt-sensitive hypertension is caused by tubulointerstitial immune cell infiltration in the 
kidney. Am J Physiol Renal Physiol 2013; 304: F982-990. 
49. Hewinson J, Mackenzie AB. P2X(7) receptor-mediated reactive oxygen and 
nitrogen species formation: from receptor to generators. Biochem Soc Trans 2007; 
35: 1168-1170. 
50. O'Connor PM, Cowley AW, Jr. Modulation of pressure-natriuresis by renal 
medullary reactive oxygen species and nitric oxide. Curr Hypertens Rep 2010; 12: 
86-92. 
51. Inscho EW. ATP, P2 receptors and the renal microcirculation. Purinergic 
signalling 2009; 5: 447-460. 
52. Johnson RJ, Rodriguez-Iturbe B, Kang DH, et al. A unifying pathway for 
essential hypertension. Am J Hypertens 2005; 18: 431-440. 
53. Brass D, Grably MR, Bronstein-Sitton N, et al. Using antibodies against P2Y 
and P2X receptors in purinergic signaling research. Purinergic signalling 2012; 8: 61-
79. 
	  	  
24	  
Figure 1: Renal function is improved by P2X7R antagonism. The selective 
P2X7R antagonist Brilliant Blue G (BBG) was infused intravenously in rats chronically 
infused with ANG II. BBG infusion improved A) mean arterial blood pressure; B) 
urinary sodium excretion; C) the acute pressure natriuresis response and; D) the 
pressure diuresis relationship in ANG II-treated rats. In A) and B) data are mean 
±SEM; in C and D, individual points are plotted with the linear regression line and 
95% confidence interval. Experiments were performed in control rats (n=7; open 
circles), ANGII-treated rats (n=5; closed squares) and ANGII+BBG (n=5, grey 
squares).  
Figure 2: P2X7R localization in renal vasculature. P2X7R was localized to the 
endothelium of preglomerular arteries. A Segmental artery from A) Vehicle and B) 
ANGII-treated rat is shown. Focal expression of P2X7R (indicated by white arrows) in 
the vascular smooth muscle was observed in ANGII treated rats, show in Figure 2Bi. 
P2X7R expression was also observed in interlobar arteries (C= vehicle; D= ANGII) 
and afferent arterioles (E=vehicle; F= ANGII).  Scale bars indicate 20µm. 
Figure 3: Chronic ANGII infusion induces renal injury. ANGII promoted 
vacuolization of myocytes in pre-glomerular arteries, particularly the larger segmental 
and interlobar arteries. A and B show exemplar images from ANGII-treated rats; C is 
from a vehicle treated rat. This injury was scored in a single blind fashion and was 
significantly higher in ANGII treated rats (Panel D; Data are mean ±SEM and 
comparison was made using unpaired T-test). Chronic ANGII infusion caused a 
modest increase in the number of glomeruli containing ED-1 positive macrophage 
staining (Panel E. Individual data are shown from control and ANGII-treated rats 
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along with the median and inter-quartile range; comparisons were made using Mann-
Whitney test). P values as shown are two-tailed.  
Figure 4: P2X7R antagonism increases renal perfusion. The specific P2X7R 
antagonist AZ11657312 caused a dose-dependent A) reduction in mean arterial 
blood pressure; B) increase in renal artery blood flow and C) increase in perfusion of 
the renal medulla in ANGII-treated rats. The area under the curve for each dose of 
drug was calculated and normalized to the effect of the saline vehicle in each rat. 
Data are mean ±SEM. ANOVA indicated a significant effect of AZ11657312 
(P<0.001) on each variable and Sidak’s multiple comparison test was used for post-
hoc comparisons. *P<0.05 for antagonist versus vehicle in the control group (n=5). 
†P<0.05, ††P<0.01, †††P<0.001 and ††††P<0.0001 for antagonist versus vehicle in the 
ANGII group (n=6). 
Figure 5: Renal vascular effects of P2X7R antagonism are nitric oxide 
dependent. The effect of the specific P2X7R antagonist AZ11657312 was assessed 
in ANGII-treated rats (n=6) before and after inhibition of nitric oxide synthase. A) 
mean arterial blood pressure;  (B), renal blood flow and (C) medullary tissue 
perfusion (C). The area under the curve for each dose of drug was calculated and 
normalized to the effect of the saline vehicle in each rat. Data are mean ±SEM. Data 
are mean ±SEM. ANOVA indicated a significant effect of AZ11657312 (P<0.001) on 
each variable and Sidak’s multiple comparison test was used for post-hoc 
comparisons. *P<0.05, **P<0.01 and ****P<0.0001 for antagonist dose compared 
with vehicle in the ANGII group. †P<0.05, ††P<0.01, †††P<0.001 and ††††P<0.0001 
compared with vehicle after infusion of L-NAME to inhibit nitric oxide production. 
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Figure 6: P2X7R antagonism improves renal oxygenation in ANGII-treated rats. 
Intravenous injection of the selective P2X7R antagonist Brilliant Blue G (shown by 
arrow) reduced R2* (i.e. improved pO2) in ANGII-treated rats (black squares; n=6) but 
not in control rats (open circles; n=6). The effect was more pronounced in A) areas of 
low basal oxygenation compared with B) the cluster of high oxygenation areas. For 
each rat, the change in R2* induced by Brilliant Blue G is expressed as a percentage 
of the baseline recordings. Data are mean±SEM. ANOVA indicated a significant 
effect of the P2X7R antagonist (P<0.05) and Sidak’s multiple comparison test was 
used for post-hoc comparison. †P<0.05, ††P<0.01, †††P<0.001 compared with 
baseline in the ANGII group.	  
	  	  	  	  
